Intrexon Buying Medistem for $26M | GenomeWeb

NEW YORK (GenomeWeb News) – Intrexon today announced an agreement to acquire adult stem cell technology firm Medistem for about $26 million.

Based in San Diego, Medistem develops endometrial regenerative cells, which are universal donor adult stem cells that stimulate new blood vessel formation. ERCs can generate different tissues such as heart, brain, pancreas, liver, bone, cartilage, and lung, and Intrexon plans to use its synthetic biology platforms to "engineer a diverse array of cell-based therapeutic candidates using Medistem's multipotent ERCs," it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.